MMIT Strategic Launch Report provides drug manufacturers with a realistic view of payers’ coverage adoption rates and utilization management within the first year post-launch.The report is paired with consensus forecast data from our partner, Evaluate, for currently approved and pipeline agents within the target indication, to help you identify competitors and challenges and proactively plan your near- and long-term strategies.
Evaluate and MMIT united in August 2021 to offer customers a unique and comprehensive data solution offering both analytical and predictive data insights across the entire drug life cycle. London-based Evaluate is a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry.
Learn when and how to select the right analogs to set the most accurate expectations and payer strategy at launch.VIEW RECORDING NOW
Learn about access barriers to the use of innovative technology such as administrative burden and reimbursement challenges.VIEW RECORDING NOW
MMIT offers a variety of payer access data and insights solutions.